title: Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene.
abstract: For DNA vaccination studies, recombinant VP1 protein of encephalomyocarditis virus (EMCV) was produced from Escherichia coli, and eukaryotic VP1 expression vector, pCT-Gs-VP1, was generated and used as a DNA vaccine. Mice were immunized intramuscularly (i.m.) with pCT-Gs-VP1 in the presence or absence of plasmid DNA expressing granulocyte-macrophage colony stimulating factor (GM-CSF), and were subsequently analyzed for their anti-VP1 immune responses with recombinant VP1 in ELISA. Immunization of mice with pCT-Gs-VP1 resulted in VP1-specific immune response and 43% protection from subsequent lethal heterologous challenge of EMCV. Coinjection of mice with pCT-Gs-VP1 and plasmid DNA encoding GM-CSF was shown to increase the seroconversion rate of the immunized mice with a single DNA injection, and enhanced to a higher degree VP1-specific immunity, which appeared to result in better protection (about 80%) from lethal virus challenge. Thus, our results provide evidence for the potential use of GM-CSF to induce better immune response and resistance against viral infection in DNA vaccination.
authors.affiliation: Department of Life Science, School of Environmental Engineering, Pohang University of Science and Technology, Kyung-buk, Korea.
authors.forename: J I
authors.initials: JI
authors.lastname: Sin
authors.forename: J H
authors.initials: JH
authors.lastname: Sung
authors.forename: Y S
authors.initials: YS
authors.lastname: Suh
authors.forename: A H
authors.initials: AH
authors.lastname: Lee
authors.forename: J H
authors.initials: JH
authors.lastname: Chung
authors.forename: Y C
authors.initials: YC
authors.lastname: Sung
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D019556:COS Cells; D002213:Capsid / Q000235:genetics* / Q000276:immunology*; D036022:Capsid Proteins; D018188:Cardiovirus Infections / Q000276:immunology* / Q000517:prevention & control*; D004279:DNA, Viral / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D004686:Encephalomyocarditis virus / Q000276:immunology*; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D012680:Sensitivity and Specificity; D014162:Transfection; D014611:Vaccination; D019444:Vaccines, DNA / Q000627:therapeutic use*
chemical_list: D036022:Capsid Proteins; D004279:DNA, Viral; C096256:VP1 protein, encephalomyocarditis virus; D019444:Vaccines, DNA; D016178:Granulocyte-Macrophage Colony-Stimulating Factor